Arterial Clot Management While on Apixaban

Pharmacokinetics and Dosing

The half-life of apixaban is 6-15 hours with normal renal function, extending to 17 hours with severe renal impairment, which informs timing of alternative anticoagulation strategies, as reported by the American College of Cardiology 1, 2

Underdosing is a common cause of thrombotic events during hospitalization, with one study showing all thromboembolic events occurred in underdosed patients, according to Thrombosis Research 3
Common reasons for inappropriate underdosing include concurrent antiplatelet use, history of bleeding, frailty concerns, and fluctuating renal function, as noted in Thrombosis Research 3

Hemodynamic stabilization and supportive care are essential initial steps in managing arterial thrombosis, as emphasized by medical guidelines, although the specific guideline society is not specified in this context, but reported in a medical insights journal 4
For other patients, options include transitioning to warfarin or investigating whether heparin bridging is appropriate depending on the clinical scenario, as discussed in Thrombosis Research 3

Approximately 80% of inappropriate DOAC prescriptions are identified by pharmacists in hospital settings, highlighting the frequency of dosing errors, according to Thrombosis Research 3
Overdosing can occur from continuation of home doses without adjusting for changing renal function or body weight, as warned in Thrombosis Research 3
If the patient was appropriately dosed and has no contraindications, the arterial thrombosis represents true anticoagulation failure, as noted in Thrombosis Research 3